|9 Months Ended|
Sep. 30, 2018
|Licenses Acquired [Abstract]|
In accordance with ASC 730-10-25-1,
Research and Development,
costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by the Company and its’ subsidiaries require substantial completion of research and development, regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the three and nine months ended September 30, 2018 and 2017, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations, as reflected in the table below:
The table below provides a summary of Checkpoint’s expense related to its licenses, for the three and nine months ended September 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
For the three and nine months ended September 30, 2018, Checkpoint recorded a $1.0 million milestone in connection with their license agreement with Dana-Farber, in connection with the achievement of dosing the 12
thpatient in the Phase 1 trial for CK-301.
See Note 21 for revenue recognized in connection with the Jubilant license under a sublicense agreement with TGTX, a related party.
In connection with Helocyte’s amended and restated license agreement for Triplex with COH, during the fourth quarterof 2018
to achieve a development milestone. The milestone relates to completion of the Phase 2 clinical trial which Helocyte deems to be probable, due to thecompletion
of thefollow-up period for the l
in the trial. For the three and nine months ended September 30, 2018 and 2017, respectively, Helocyte recorded expense of $1.5 million and nil, and $1.5 million andnil, respectively,
in connection with this license.
On August 2, 2018, Mustang entered into an exclusive worldwide license agreement with St. Jude Children’s Research Hospital(“St. Jude”)
for the development of a first-in-class ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“X-SCID”), also known as bubble boy disease. The therapy is currently being evaluated in a Phase 1/2 multicenter trial in infants under the age of two. This study is the world’s first lentiviral gene therapy trial for infants with X-SCID. Mustang paid an upfront fee of $1.0 million in August 2018 under the licensein addition to an annual maintenance fee of $0.1 million (beginning in 2019). St. Jude is also
eligible to receive milestone payments totaling up to $13.5million, upon and subject to the achievement of five development and commercialization milestones. Royalty payments in the mid-single digits are due on net sales of licensed products. Mustang is obligated to pay to St. Jude a percentage of certain revenues received in connection with a sublicense that is in the mid-teens, regardless of when such sublicense is executed
The table below provides a summary of Mustang’s expense related to its licenses, for the three and nine months ended September 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
For the three and nine months ended September 30, 2018 and 2017, respectively, Caelum recorded expense of approximately $0.2 and nil, and $0.2 and $0.2 million in connection with its license for CAEL-101 from Columbia University.
For the three and nine months ended September 30, 2018 and 2017, respectively, Cyprium recorded no expense in 2018 and nil and $0.1 million in 2017, in connection with its license for CUTX-101 (copper histidinate injection) from the
Eunice Kennedy Shriver
National Institute of Child Health and Human Development (“NICHD”).